Log in or Sign up for Free to view tailored content for your specialty!
Schizophrenia News
Evenamide boosts symptom improvement in treatment-resistant schizophrenia
Evenamide, an investigational drug for treatment-resistant schizophrenia, was linked with “increasing, sustained and clinically significant” symptom improvements in a recent study, according to a manufacturer press release.
Study finds no associations between various mental health conditions and results after TJA
Published results showed no statistically significant associations between mental health conditions, such as depression, anxiety, bipolar disorder, trauma and schizophrenia, and outcomes after total joint arthroplasty.
Log in or Sign up for Free to view tailored content for your specialty!
Karuna Therapeutics submits new drug application to FDA for schizophrenia treatment
Karuna Therapeutics Inc. has submitted a new drug application to the FDA for KarXT, its investigational muscarinic antipsychotic for the treatment of schizophrenia.
‘Don’t give up’: Catatonic woman wakes up after 20 years following treatment for lupus
A woman diagnosed with schizophrenia and psychosis who was nonverbal and nonresponsive for 2 decades recently “woke” after treatment with pulse steroids and cyclophosphamide.
Atopic dermatitis may be associated with schizophrenia, schizoaffective disorder
Atopic dermatitis was associated with increased odds for schizophrenia and schizoaffective disorder, according to a study published in Archives of Dermatological Research.
Once-daily schizophrenia treatment falls short of endpoints in two phase 3 trials
Two phase 3 studies of a once-daily treatment for schizophrenia failed to meet their primary endpoints, with developers pointing to placebo effects and disruption from the COVID-19 pandemic to possibly explain the drug’s performance.
Symptom dimensions within bipolar disorder may have distinct causes
Symptom dimensions within bipolar disorder may have distinct causes, supporting the hypothesis that genetic heterogeneity underpins clinical heterogeneity, according to a study published in The Lancet Psychiatry.
KarXT reduces symptom severity in schizophrenia
MIAMI BEACH, Fla. — Treatment with KarXT reduced symptom severity for those with schizophrenia and acute psychosis compared with placebo, according to research presented at the American Society of Clinical Psychopharmacology annual meeting.
Lifetime duration of cannabis use, cognition linked in schizophrenia
SAN FRANCISCO — Among people with schizophrenia, lifetime duration of cannabis use was associated with cognitive function, according to a poster presented at the American Psychiatric Association annual meeting.
Link between cannabis use disorder, schizophrenia strongest in young men
The association between cannabis use disorder and schizophrenia was stronger in men compared with women, particularly among people aged 16 to 20 years, according to a study published in Psychological Medicine.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read